Press coverage about Incyte Corporation (NASDAQ:INCY) has been trending positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte Corporation earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 73 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Leerink’s Porges says Incyte good target for Gilead (seekingalpha.com)
- Investors Swarm in on Incyte Corporation (NASDAQ:INCY) and Ryanair Holdings plc (NASDAQ:RYAAY) Shares – FLBC News (flbcnews.com)
- Brokerages Expect Incyte Corporation (NASDAQ:INCY) Will Announce Earnings of -$0.05 Per Share (americanbankingnews.com)
- Merus Announces First Quarter 2017 Financial Re… (trustnet.com)
- Zoetis Inc. (ZTS) registers a price change of 1.29% while Incyte Corporation (INCY) finishes with a flow of 2.85% – Stocks Gallery (stocksgallery.com)
Several analysts have weighed in on the company. Barclays PLC set a $135.00 price target on Incyte Corporation and gave the company a “buy” rating in a report on Saturday, April 8th. BMO Capital Markets raised their price target on Incyte Corporation from $140.00 to $170.00 and gave the company an “outperform” rating in a report on Monday, April 3rd. TheStreet raised Incyte Corporation from a “d+” rating to a “c” rating in a report on Wednesday, May 24th. Cowen and Company reiterated a “buy” rating on shares of Incyte Corporation in a research report on Monday, June 5th. Finally, Credit Suisse Group reiterated a “buy” rating on shares of Incyte Corporation in a research report on Saturday, June 10th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Incyte Corporation currently has an average rating of “Buy” and a consensus target price of $141.88.
Incyte Corporation (NASDAQ INCY) traded up 0.64% during mid-day trading on Friday, reaching $134.27. The company’s stock had a trading volume of 737,510 shares. Incyte Corporation has a one year low of $75.52 and a one year high of $153.15. The stock has a 50-day moving average price of $126.52 and a 200-day moving average price of $124.71. The company’s market capitalization is $27.50 billion.
Incyte Corporation (NASDAQ:INCY) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.97) by $0.01. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. The firm had revenue of $384.08 million for the quarter, compared to analysts’ expectations of $359.19 million. During the same period last year, the firm earned $0.12 EPS. The company’s quarterly revenue was up 45.8% on a year-over-year basis. Equities research analysts forecast that Incyte Corporation will post ($0.72) EPS for the current year.
In other Incyte Corporation news, insider Paul Trower sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $126.18, for a total value of $378,540.00. Following the transaction, the insider now directly owns 12,148 shares of the company’s stock, valued at approximately $1,532,834.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric H. Siegel sold 1,820 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $126.20, for a total transaction of $229,684.00. Following the completion of the transaction, the executive vice president now directly owns 20,036 shares in the company, valued at $2,528,543.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have bought 1,500 shares of company stock worth $185,530 and have sold 47,275 shares worth $5,758,636. 13.70% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Incyte Corporation (NASDAQ:INCY) Getting Positive News Coverage, Report Finds” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/07/15/incyte-corporation-nasdaqincy-getting-positive-news-coverage-report-finds.html.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.